Bispecific Antibodies

Dual-Targeting Therapeutic Molecules

In the competitive landscape of biotherapeutics, your lead candidate’s success depends on structural purity and functional potency. Leinco Technologies provides a premium catalog of off-the-shelf therapeutic and custom-engineered bispecific antibody production services (BsAbs). 

Our products are curated for maximum stability, offering the pharmacokinetic profiles of native IgGs with the revolutionary multi-specificity required for modern immunotherapy. We also provide ultra-pure and biologically active recombinant proteins to complement your bispecific antibody research needs.

The Product Core: Advanced Bispecific Architectures

We deliver high-homogeneity biosimilar molecules across four primary structural classes. Each product is validated for affinity, thermal stability, and low-aggregation profiles.

Dual Pathway Blockade

The gold standard for therapeutic longevity. Utilizing charge-pair Mutation and knob-in-hole technology, these products offer:

  • Native Half-Life: Full Fc-mediated recycling via FcRn.
  • Purity: >98% correctly paired heterodimers, reducing the risk of homodimer-induced off-target toxicity.
  • Effector Control: Available in IgG1, IgG4, or effector-silent LALA-PG backbones.

Bispecific T-Cell Engagers

Highly potent, low-molecular-weight constructs designed for rapid tumor penetration and redirected T-cell cytotoxicity.

  • Architecture: Tandem scFv fragments (Tarlatumab) connected by optimized flexible linkers.
  • Application: Ideal for CD3-mediated immune synapse formation and solid tumor infiltration.

Multivalent & Multi-Specific Scaffolds

For complex signaling pathways, we provide tetravalent molecules and trispecific engagers.

  • Enhanced Avidity: Dual-binding for each antigen to overcome low-density receptor targets.
  • Dual Checkpoint Inhibition: Single-molecule blockade of pathways like PD-1/CTLA-4 or LAG-3/TIM-3.

Technical Specifications & Quality Benchmarks

Every Leinco bispecific product is a “Ready-to-Use” reagent, manufactured under ISO 13485:2016 standards to ensure seamless transition from in vitro assays to in vivo models.

Feature Specification Validation Method
Purity >95% by Monomer Content SDS-PAGE
Endotoxin <1 EU/mg (Ultra-Low) LAL Kinetic Chromogenic
Affinity Sub-nanomolar to Picomolar SPR (Biacore) / BLI
Aggregation <5% Aggregate Content SEC-HPLC
Host System HEK-293 or CHO Recombinant Expression

Categories

Filters

Name
Applications
Prod No.
Clone
Availability

Why Leinco Products

When you choose a Leinco-engineered product, you are purchasing more than a protein—you are securing a commercially viable molecular scaffold.

  • US-Based Manufacturing: Eliminate the lead times and IP risks associated with international sourcing.
  • Audit-Ready Documentation: Every product comes with a comprehensive Certificate of Analysis (CoA) and full sequence traceability.
  • Scalable Continuity: The exact molecule you use in the pilot phase is produced using the same recombinant platform for your gram-scale requirements.
  • Customization on Demand: Need a specific paratope? Our services take your sequence and delivers a purified, formulated bispecific in as little as 10 weeks.

Technical Note: All Leinco bispecific products are biosimilars formulated for high-concentration stability (>10 mg/mL) to support subcutaneous delivery research and high-dose in vivo studies without precipitation or loss of activity.

Questions or Comments?

Explore our inventory of validated bispecific scaffolds or initiate a custom build for your proprietary targets. Leinco also produces a wide variety of highly bioactive and pure recombinant proteins

View Bispecific Catalog Consult Sales